Burnaby, British Columbia – January 6, 2025 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
Burnaby, British Columbia – December 16, 2024 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
Burnaby, British Columbia – December 14, 2022 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >